Preferential depletion of tcf1+ progenitor t-cells in severe covid-19 as mediated by interleukin 12 (il-12)
AssigneeChristopher Rudd
InventorChristopher Rudd
Life of this patent
Estimating the term…
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to global public health. While some individuals exhibit mild symptoms, others develop severe disease leading to severe lymphopenia and death. Provided herein are methods for determining whether a subject suffering from a SARS-Cov-2 infection is more likely to suffer from severe or mild disease. Also provided are methods for predicting whether a subject suffering from a SARS-Cov-2 infection with mild disease will progress to more severe disease and methods for treating patients having an infection via SARS-Cov-2 and related family members.
Claims25
A method of determining whether a subject suffering from an acute respiratory syndrome coronavirus infection is more likely to suffer from severe or mild disease comprising detecting the amount of transcription factor TCF1+ (T-cell factor-1) and in addition, any one or more chosen from:
- Ki67, LEF1, Notch1, Eomes, Bcl2 or Caspase 3 in T cells in a biological sample comprising T cells that were isolated from the subject and comparing a measured amount to a reference amount, wherein a modified measured amount compared to the reference amount is indicative that the subject will suffer from severe or mild SARS, and optionally wherein the coronavirus is a SARS-Cov-2 coronavirus infection.
(canceled)
(canceled)
A method for treating acute respiratory syndrome coronavirus 2 (SARS-Cov-2 or SARS) infection and having a reduced amount of transcription factor TCF1+ (T-cell factor-1) expressing T cells comprising administering an effective amount of a therapy to treat severe SARS disease, and optionally wherein the coronavirus 2 (SARS-Cov-2 or SARS) infection.
-25. (canceled)
A method of predicting whether a subject suffering from an acute respiratory syndrome coronavirus infection with mild disease will progress to severe disease and possible death by detecting the expression of one or a combination of markers selected from:
- transcription factor TCF1, transcription factor EOMES, the surrogate cell surface marker for TCF1 termed SLAMF6, the proliferation marker Ki67, the pro-survival marker BcL-2 and the marker for cell death Caspase 3 in T cells in a biological sample comprising T cells that were isolated from the subject and comparing a measured amount to a reference amount, wherein a modified measured amount compared to the reference amount is indicative that the subject will suffer from severe or mild SARS disease, and optionally wherein the coronavirus 2 (SARS-Cov-2 or SARS) infection.
-42. (canceled)
A method for monitoring disease state in a subject suffering from an acute respiratory syndrome coronavirus infection comprising detecting the amount of transcription factor TCF1+ (T-cell factor-1) and in addition, any one or more chosen from:
- Ki67, LEF1, Notch1, Eomes, Bcl2 or Caspase 3 in T cells in a biological sample comprising T cells that were isolated from the subject and comparing a measured amount to a reference amount, wherein a modified measured amount compared to the reference amount is indicative of the status of the coronavirus infection.
-54. (canceled)
Dependencies are inferred from the claim text.